Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

101. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

2009 Health Technology Assessment (HTA) Database.

102. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Full Text available with Trip Pro

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism.In a randomized, double-blind, noninferiority trial involving patients with acute venous thromboembolism who were initially given parenteral anticoagulation therapy for a median of 9 days (interquartile range, 8 to 11), we compared oral (...) dabigatran, administered at a dose of 150 mg twice daily, with warfarin that was dose-adjusted to achieve an international normalized ratio of 2.0 to 3.0. The primary outcome was the 6-month incidence of recurrent symptomatic, objectively confirmed venous thromboembolism and related deaths. Safety end points included bleeding events, acute coronary syndromes, other adverse events, and results of liver-function tests.A total of 30 of the 1274 patients randomly assigned to receive dabigatran (2.4

2009 NEJM Controlled trial quality: predicted high

103. Dabigatran versus warfarin in patients with atrial fibrillation. Full Text available with Trip Pro

Dabigatran versus warfarin in patients with atrial fibrillation. Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted (...) -dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism.Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P

2009 NEJM Controlled trial quality: predicted high

104. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157) Overview | Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | Guidance | NICE Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults Technology appraisal guidance [TA157] Published date: 24 September 2008 Share Guidance on dabigatran etexilate (Pradaxa

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

105. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. (Abstract)

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment (...) for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after surgery, or subcutaneous enoxaparin 40 mg once daily (1162), starting the evening before surgery. The primary efficacy outcome was the composite of total venous thromboembolism (venographic or symptomatic) and death from all causes during treatment. On the basis of the absolute difference in rates of venous thromboembolism with enoxaparin versus placebo, the non-inferiority

2007 Lancet Controlled trial quality: predicted high

106. Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing

Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This study examines the use of dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery. Timeliness warning Available on request from NHSC. Final

2006 Health Technology Assessment (HTA) Database.